Explore 3 Stock Ideas & Industry Insights Download Free Report

Stocks

Colliers continues to enhance engineering offering in Canada

Colliers International Group Inc West-coast acquisition expands geographic footprint and scale TORONTO and NANAIMO, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- Colliers (NASDAQ, TSX: CIGI) announced today that its Canadian engineering platform Englobe Corporation (“Englobe”) has acquired Herold Engineering Limited (“Herold”), a leading …

EODHD | 16 May 2025

Applied Materials Announces Second Quarter 2025 Results

Applied Materials, Inc. Revenue $7.10 billion, up 7 percent year over year GAAP gross margin 49.1 percent and non-GAAP gross margin 49.2 percent GAAP operating margin 30.5 percent and non-GAAP operating margin 30.7 percent Record GAAP EPS $2.63 and record non-GAAP EPS $2.39, up …

EODHD | 16 May 2025

Alliance Entertainment Reports Third Quarter Fiscal Year 2025 Results

Delivered $1.9M in net income, a $5.3M year-over-year improvement, showcasing strong execution and margin gains Reduced revolver debt by 25% year-over-year, strengthening balance sheet and liquidity position Direct to Consumer sales reach 35% of gross revenue PLANTATION, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- …

EODHD | 16 May 2025

Doximity Announces Fourth Quarter and Fiscal Year 2025 Financial Results

Q4 total revenues of $138.3 million, up 17% year-over-year Q4 operating cash flow of $98.5 million, up 54% year-over-year Q4 free cash flow of $97.0 million, up 56% year-over-year Fiscal year 2025 total revenues of $570.4 million, up 20% year-over-year Fiscal year 2025 operating …

EODHD | 16 May 2025

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune …

EODHD | 16 May 2025

CORRECTING AND REPLACING - Katapult Delivers 15.4% Gross Originations and 10.6% Revenue Growth in the First Quarter, Above Outlook

Expects Growth to Accelerate In Second Quarter Reiterates 2025 Guidance PLANO, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- In the press release issued by Katapult Holdings, Inc. on May 15, 2025, in the gross originations by quarter table, Q4 in FY 2024 should be …

EODHD | 16 May 2025

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook …

EODHD | 16 May 2025

374Water Reports First Quarter 2025 Financial Results

Multiple Deployments Scheduled throughout 2025 to Showcase AirSCWO Technology Launched Waste Destruction Services and Signed RCRA Part B TSDF Partner Agreement to Expand Onsite Operations New Executive Team and Director Appointments to Drive Commercial Trajectory DURHAM, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- 374Water …

EODHD | 16 May 2025

Sempra Declares Common Dividend

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Sempra (NYSE: SRE) today announced that its board of directors has declared a $0.645 per share quarterly dividend on the company's common stock, which is payable July 15, 2025, to common stock shareholders of record at the …

EODHD | 16 May 2025

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical …

EODHD | 16 May 2025